186 related articles for article (PubMed ID: 6293813)
21. Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.
Fung-Tomc J; Dougherty TJ; DeOrio FJ; Simich-Jacobson V; Kessler RE
Antimicrob Agents Chemother; 1989 Apr; 33(4):498-502. PubMed ID: 2499250
[TBL] [Abstract][Full Text] [Related]
22. [Pseudomonas aeruginosa: acquired in vitro resistance to beta-lactams].
Thabaut A; Meyran M
Pathol Biol (Paris); 1983 May; 31(5):387-91. PubMed ID: 6413939
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
Yamaguchi K; Mathai D; Biedenbach DJ; Lewis MT; Gales AC; Jones RN
Diagn Microbiol Infect Dis; 1999 Jun; 34(2):123-34. PubMed ID: 10354863
[TBL] [Abstract][Full Text] [Related]
24. Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem.
Spangler SK; Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1996 Mar; 40(3):772-5. PubMed ID: 8851609
[TBL] [Abstract][Full Text] [Related]
25. Use of cefotaxime or ceftazidime susceptibility tests for predicting susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa.
Heym B; Lacroix O; Péan Y; Gertner J; Nicolas MH; Jarlier V
J Antimicrob Chemother; 1994 Apr; 33(4):729-35. PubMed ID: 8056691
[TBL] [Abstract][Full Text] [Related]
26. Belgian multicentre study on the in vitro activity of cefepime against gram-negative bacilli.
Verbist L; Glupczynski Y
Acta Clin Belg; 1996; 51(1):28-35. PubMed ID: 8669160
[TBL] [Abstract][Full Text] [Related]
27. Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa.
Voutsinas D; Mavroudis T; Avlamis A; Giamarellou H
Eur J Clin Microbiol Infect Dis; 1989 Oct; 8(10):917-9. PubMed ID: 2512141
[TBL] [Abstract][Full Text] [Related]
28. [In vitro comparative activity of 4 beta-lactams against Pseudomonas aeruginosa. Role of cefoperazone].
Joly-Guillou ML; Bergogne-Berezin E; Verin-Prevost C
Pathol Biol (Paris); 1984 May; 32(5):408-11. PubMed ID: 6429612
[TBL] [Abstract][Full Text] [Related]
29. Antibacterial activity of N-formimidoyl thienamycin in comparison with cefotaxime, lamoxactam, cefoperazone, piperacillin gentamicin.
Braveny I; Machka K; Elsser R
Infection; 1982 Jan; 10(1):45-9. PubMed ID: 6279523
[TBL] [Abstract][Full Text] [Related]
30. In-vitro activity of cefpirome compared with that of other agents.
Raizes EG; Cantey JR
J Antimicrob Chemother; 1988 Feb; 21(2):177-81. PubMed ID: 3129388
[TBL] [Abstract][Full Text] [Related]
31. [In vitro antibacterial activity of a new cephalosporin: cefpirome (HR 810). Comparison with ceftriaxone, cefotaxime, latamoxef and ceftazidime].
Le Noc P; Bryskier A; Le Noc D
Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):567-71. PubMed ID: 3534744
[TBL] [Abstract][Full Text] [Related]
32. Fourth-generation cephalosporins: in vitro activity against nosocomial gram-negative bacilli compared with beta-lactam antibiotics and ciprofloxacin.
Tumah H
Chemotherapy; 2005 May; 51(2-3):80-5. PubMed ID: 15870501
[TBL] [Abstract][Full Text] [Related]
33. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the in-vitro activities of ceftazidime and new cephalosporins against 107 strains of Pseudomonas aeruginosa and 249 strains of cefazolin-resistant Enterobacteriaceae.
Thabaut A; Durosoir JL; Saliou P
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():123-5. PubMed ID: 19810174
[TBL] [Abstract][Full Text] [Related]
35. Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
Phillips I; Warren C; Shannon K; King A; Hanslo D
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():23-31. PubMed ID: 19802967
[TBL] [Abstract][Full Text] [Related]
36. The in vitro activity of ceftazidime against resistant clinical isolates.
Van Landuyt HW; Denolf BL; Pyckavet M; Lambert AM
Infection; 1983; 11 Suppl 1():S23-7. PubMed ID: 6299967
[TBL] [Abstract][Full Text] [Related]
37. In-vitro activity of ceftazidime, a beta-lactamase stable cephalosporin.
Neu HC
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():131-4. PubMed ID: 19810175
[TBL] [Abstract][Full Text] [Related]
38. In-vitro comparison of ceftazidime and nine other antimicrobial agents against hospital strains of Gram-negative bacteria.
Wilkinson LD; Gentry LO
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():53-6. PubMed ID: 19802969
[TBL] [Abstract][Full Text] [Related]
39. GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae.
Verbist L; Verhaegen J
Antimicrob Agents Chemother; 1980 May; 17(5):807-12. PubMed ID: 6994640
[TBL] [Abstract][Full Text] [Related]
40. In-vitro antibacterial activity of imipenem compared with four other beta-lactam antibiotics (ceftazidime, cefotaxime, piperacillin and azlocillin) against 828 separate clinical isolates from a Portuguese hospital.
Santos-Ferreira MO; Vital JO
J Antimicrob Chemother; 1986 Dec; 18 Suppl E():23-6. PubMed ID: 3469195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
